---
figid: PMC5730634__10557_2017_6757_Fig1_HTML
figlink: /pmc/articles/PMC5730634/figure/Fig1/
number: Fig. 1
caption: Potential effects of vascular disease treatment on pMV release. Increase
  in intraplatelet calcium concentration is the principal step in pMV formation. ADP
  receptor inhibitors increase the intraplatelet concentration of cAMP thereby decreasing
  platelet vesiculation. GP IIb-IIIa antagonists inhibit binding of fibrinogen thereby
  preventing the second wave of platelet activation. Statins inhibit platelet vesiculation
  multi-directional—reducing NF-κB activity and increasing exposure of PPARs and via
  the ROCK pathway. Fibrates as PPAR agonists increase the levels of both cAMP and
  cGMP and decrease calcium concentration. Calcium channel blockers inhibit calcium
  influx and decrease intracellular calcium concentration. Platelet-derived microvesicles
  transfer AA between platelets and ECs. Microvesicles also metabolize AA to TXA2.
  AA arachidonic acid, ADP adenosine diphosphate, ASA acetylsalicylic acid, COX cyclooxygenase,
  GP glycoprotein, MLCP myosin light chain phosphatise, MAPK mitogen-activated protein
  kinase, NF-κB nuclear factor kappa B, PDE phosphodiestherase, PGH2 prostaglandin
  H2, PKC protein kinase C, PLA2 phospholipase A2, PLT platelet, p38MAPK mitogen-activated
  protein kinase p38, pMV platelet-derived microvesicles, PPAR peroxisome proliferator-activated
  receptor, PS phosphatidylserine, PUFAs polyunsaturated fatty acids, ROCK Rho-associated
  protein kinase, TNF-α tumor necrosis factor α, TXA2 thromboxane A2, TXA2R thromboxane
  A2 receptor
pmcid: PMC5730634
papertitle: The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.
reftext: Justyna Rosińska, et al. Cardiovasc Drugs Ther. 2017;31(5):627-644.
pmc_ranked_result_index: '182994'
pathway_score: 0.9104021
filename: 10557_2017_6757_Fig1_HTML.jpg
figtitle: Effects of vascular disease treatment on pMV release
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5730634__10557_2017_6757_Fig1_HTML.html
  '@type': Dataset
  description: Potential effects of vascular disease treatment on pMV release. Increase
    in intraplatelet calcium concentration is the principal step in pMV formation.
    ADP receptor inhibitors increase the intraplatelet concentration of cAMP thereby
    decreasing platelet vesiculation. GP IIb-IIIa antagonists inhibit binding of fibrinogen
    thereby preventing the second wave of platelet activation. Statins inhibit platelet
    vesiculation multi-directional—reducing NF-κB activity and increasing exposure
    of PPARs and via the ROCK pathway. Fibrates as PPAR agonists increase the levels
    of both cAMP and cGMP and decrease calcium concentration. Calcium channel blockers
    inhibit calcium influx and decrease intracellular calcium concentration. Platelet-derived
    microvesicles transfer AA between platelets and ECs. Microvesicles also metabolize
    AA to TXA2. AA arachidonic acid, ADP adenosine diphosphate, ASA acetylsalicylic
    acid, COX cyclooxygenase, GP glycoprotein, MLCP myosin light chain phosphatise,
    MAPK mitogen-activated protein kinase, NF-κB nuclear factor kappa B, PDE phosphodiestherase,
    PGH2 prostaglandin H2, PKC protein kinase C, PLA2 phospholipase A2, PLT platelet,
    p38MAPK mitogen-activated protein kinase p38, pMV platelet-derived microvesicles,
    PPAR peroxisome proliferator-activated receptor, PS phosphatidylserine, PUFAs
    polyunsaturated fatty acids, ROCK Rho-associated protein kinase, TNF-α tumor necrosis
    factor α, TXA2 thromboxane A2, TXA2R thromboxane A2 receptor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - COX5A
  - COX10
  - COX8C
  - COX4I2
  - PRKCD
  - PRKCE
  - COX7B2
  - PRKCB
  - COX8A
  - PDE3B
  - COX11
  - COX7B
  - WDTC1
  - COX17
  - COX6B2
  - COX15
  - ROCK2
  - TNF
  - NFKB1
  - COX4I1
  - PRKCA
  - PRKCG
  - COX6A1
  - PRKD3
  - ROCK1
  - COX7A1
  - COX7A2
  - PRKCH
  - P2RY12
  - PDE3A
  - FGA
  - FGG
  - PRKCI
  - FGB
  - PRKCQ
  - PRKCZ
  - COX5B
  - COX6B1
  - COX6A2
genes:
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX5A
  entrez: '9377'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX10
  entrez: '1352'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX8C
  entrez: '341947'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX4I2
  entrez: '84701'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7B2
  entrez: '170712'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX8A
  entrez: '1351'
- word: PDE3
  symbol: PDE3
  source: bioentities_symbol
  hgnc_symbol: PDE3B
  entrez: '5140'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX11
  entrez: '1353'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7B
  entrez: '1349'
- word: ADP
  symbol: ADP
  source: hgnc_alias_symbol
  hgnc_symbol: WDTC1
  entrez: '23038'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX17
  entrez: '10063'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6B2
  entrez: '125965'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX15
  entrez: '1355'
- word: ROCK
  symbol: ROCK
  source: bioentities_symbol
  hgnc_symbol: ROCK2
  entrez: '9475'
- word: TNF-a
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX4I1
  entrez: '1327'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6A1
  entrez: '1337'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: ROCK
  symbol: ROCK
  source: bioentities_symbol
  hgnc_symbol: ROCK1
  entrez: '6093'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7A1
  entrez: '1346'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7A2
  entrez: '1347'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: P2Y12
  symbol: P2Y12
  source: hgnc_alias_symbol
  hgnc_symbol: P2RY12
  entrez: '64805'
- word: PDE3
  symbol: PDE3
  source: bioentities_symbol
  hgnc_symbol: PDE3A
  entrez: '5139'
- word: fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGA
  entrez: '2243'
- word: fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGG
  entrez: '2266'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGB
  entrez: '2244'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX5B
  entrez: '1329'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6B1
  entrez: '1340'
- word: COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6A2
  entrez: '1339'
chemicals: []
diseases: []
---
